Administration of exogenous CD91 promoteshemin clearance, reduces oxidative stress and neuronal damage, and markedlydecreases hematoma volume and neurological deficits, while these neuroprotectiveeffects are partially reversed by CD91 siRNA. This evidence concerns the gene LRP1 and hematoma.